Abstract
Purpose: Our goal was to determine if the addition of norethindrone acetate (NETA) to leuprolide acetate (LA) has an adverse effect on controlled ovarian stimulation (COH) during in vitro fertilization (IVF).
Methods: Forty-one consecutive patients undergoing COH and IVF were divided into two groups and evaluated. Group 1 consisted of 18 patients who did not become pregnant following two cycles (one of each protocol). Group 2 consisted of 23 patients who became clinically pregnant following one cycle from either protocol. The standard protocol consisted of LA (1 mg) injected subcutaneously from the first day of menses until day 8 or when ovarian suppression was evident, at which time the dose was halved and COH was initiated. The study protocol was identical except 10 mg of NETA was given orally with LA for the first 8 days. Ovarian stimulation was similar in each protocol.
Results: No adverse effect on ovarian stimulation was evident on the addition of NETA to LA. No differences were noted in days of stimulation, peak estradiol (E2) level attained, peak E2-to-oocyte ratio, dosage of exogenous gonadotropins, number of aspirated oocytes, fertilization rate, or oocyte and preembryo quality.
Conclusions: The addition of NETA does not attenuate COH in women undergoing IVF.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS: Induction of ovulation for in-vitro fertilization using buserelin and gonadotropins. Lancet 1984;2:1284–1285
Neveu S, Hedon B, Bringer J, Chinchole JM, Arnal F, Humeau C, Cristol P, Viala JL: Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil Steril 1987;47:639–643
Yen SSC: Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs. Fertil Steril 1983;29:257–266
Sampaio M, Serra V, Miro F, Calatayud C, Castellvi RM, Pellicer A: Development of ovarian cysts during gonadotropin-releasing hormone agonists (GnRHa), administration. Hum Reprod 1991;6:194–197
Cassidenti DL, Sauer MV, Paulson RJ, Ditkoff EC, Rivier J, Yen SS, Lobo RA: Comparison of intermittent and continuous use of a gonadotropin releasing hormone antagonist (Nal-Glu) in in vitro fertilization: A preliminary report. Am J Obstet Gynecol 1991;165:1790–1794
Ditkoff EC, Cassidenti DL, Paulson RJ, Sauer MV, Paul L, Rivier J, Yen SSC, Lobo RA: The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am J Obstet Gynecol 1991;165:1811–1817
Gerli S, Remohi J, Partrizio P, Borrero C, Balmaceda JP, Silber SJ, Asch RH: Programming of ovarian stimulation with norethindrone acetate in IVF/GIFT cycles. Hum Reprod 1989;4:746–748
Kemeter P, Feichtinger W: Experience with a new fixed stimulation protocol without hormone determinations for programmed oocyte retrieval for in-vitro fertilization. Hum Reprod 1989;4:53–58
Hugues JN, Attalah M, Herve F, Martin-Pont B, Kottler ML, Santarelli J: Effects of short-term GnRH agonist-human menopausal gonadotropin stimulation in patients pre-treated with progestogen. Hum Reprod 1992;7:1079–1084
Franco JG, Baruffi RLR, Mauri AL, Petersen CG, Campos MS: Semiprogrammed ovarian stimulation as the first choice in in-vitro fertilization programmes. Hum Reprod 1995;10:568–571
Gonzalez P, Maloul S, Ciuffardi I, Frederick JL, Balmaceda JP, Asch RH: The use of progestins for programming assisted reproductive cycles and gonadotropin-releasing hormone agonist flare-up protocols in older patients. Fertil Steril 1995;63:249–251
Neal GS, Sultan KM, Liu HC, Davis OK, Rosenwaks Z: A dual approach to ovarian suppression using oral contraceptive pills and leuprolide acetate in high responder patients undergoing IVF. Presentation at the American Fertility Society conjointly with the Canadian Fertility and Andrology Society, 1993, P-065 (abstract)
Anderson RE, Stein AL, Paulson RJ, Stanczyk FZ, Vijod AG, Lobo RA: Effects of Norethindrone on gonadotropin and ovarian steroid secretion when used for cycle programming during in vitro fertilization. Fertil Steril 1990;59:96–101
Poindexter AN 3, Dildy GA, Brody SA, Snabes MC, Brodyand SA: The effects of a long-acting progestin on the hypothalamicpituitary-ovarian axis in women with normal menstrual cycles. Contraception 1993;48:37–45
Hemrika DJ, Slaats EH, Kennedy JC, de Vries Robles-Korsen TJ, Shoemaker J: Pulsatile luteinizing hormone patterns in long term oral contraceptive users. J Clin Endocrinol Metab 1993;77:420–426
Ditkoff EC, Sauer MV: A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin-releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation. Hum Reprod 1996;11:101–103
Veeck, L.: Atlas of the Human Oocyte and Early Conceptus, Vol 2. Baltimore, Williams & Wilkins, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ditkoff, E.C., Prosser, R., Zimmermann, R.C. et al. The addition of norethindrone acetate to leuprolide acetate for ovarian suppression has no adverse effect on ovarian stimulation. J Assist Reprod Genet 14, 92–96 (1997). https://doi.org/10.1007/BF02765777
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02765777